We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 145

Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin
  • Gowling Lafleur Henderson LLP
  • Canada
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"


Solvay v Apotex; 55.2 proceeding; March 6, 2008; pantoprazole, application for prohibition dismissed
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 21 2008

The Court dismissed the application on the basis that Altana had not proven that the allegation of non-infringement was not justified


Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record


Lundbeck v. Cobalt, Genpharm and Apotex
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 7 2009

The Court granted prohibition in respect of each of the proceedings against each defendant


Sanofi v Riva; 55.2 proceeding; March 4, 2008; ramipril
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 21 2008

The Court dismissed an application for an order of prohibition based on non-infringement


Federal court affirms standing for innovative drug manufacturer
  • Gowling Lafleur Henderson LLP
  • Canada
  • July 23 2014

What rights do innovative drug manufacturers have in situations where generics challenge certain Health Canada decisions but do not name the


Recent cases
  • Gowling Lafleur Henderson LLP
  • Canada
  • August 1 2008

The Court of Appeal overturned the motions judge's decision striking the notice of appearance


PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma
  • Gowling Lafleur Henderson LLP
  • Canada
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case


Data protection: defining innovative drug in Canada
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994


Pfizer v. Apotex, PMNOC Regulations decision
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 21 2010

Apotex alleged in its NOA that Pfizer's patent was invalid for double patenting, anticipation, obviousness, lack of utility and over-breadth